1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-A0069R
    Doxylamine succinate (Standard) 562-10-7 98%
    Doxylamine succinate (Standard) is the analytical standard of Doxylamine succinate (HY-A0069). This product is intended for research and analytical applications. Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia.
    Doxylamine succinate (Standard)
  • HY-A0069S
    Doxylamine-d5 succinate 1216840-94-6 ≥98.0%
    Doxylamine-d5 succinate is deuterium labeled Doxylamine succinate (HY-A0069A). Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia.
    Doxylamine-d5 succinate
  • HY-A0078S
    Mebeverine-d6 hydrochloride 1329647-20-2 ≥98.0%
    0
    Mebeverine-d6 hydrochloride
  • HY-A0152R
    D-Thyroxine (Standard) 51-49-0
    D-Thyroxine (Standard) is the analytical standard of D-Thyroxine (HY-A0152). This product is intended for research and analytical applications. D-Thyroxine (D-T4) is an orally active thyroid hormone that inhibits the secretion of TSH. D-Thyroxine can inhibit goiter, promote metamorphosis of tadpoles and influence cholesterol metabolism. D-Thyroxine can be used for the study of hypercholesterolemia.
    D-Thyroxine (Standard)
  • HY-A0213B
    Tiludronate disodium hemihydrate 155453-10-4 98%
    Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H+-ATPase. Antiresorptive and anti-inflammatory properties.
    Tiludronate disodium hemihydrate
  • HY-A0245R
    Dihydrotachysterol (Standard) 67-96-9
    1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (Standard) is the analytical standard of 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC. This product is intended for research and analytical applications. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (POPC), a phospholipid, is a major component of biological membranes. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC is used for the preparation of liposomes and studying the properties of lipid bilayers.
    Dihydrotachysterol (Standard)
  • HY-A0287A
    Clomiphene hydrochloride 57049-00-0 98%
    Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) hydrochloride is an orally active ovulation-inducing agent. Clomiphene hydrochloride binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene hydrochloride can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene hydrochloride ameliorates memory impairment in PCOS models. Clomiphene hydrochloride mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene hydrochloride can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer.
    Clomiphene hydrochloride
  • HY-B0012B
    Pamidronic acid sodium 89131-02-2 98%
    Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronic acid sodium
  • HY-B0025R
    Voglibose (Standard) 83480-29-9
    Voglibose (Standard) is the analytical standard of Voglibose. This product is intended for research and analytical applications. Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis[1].
    Voglibose (Standard)
  • HY-B0027R
    Valnemulin hydrochloride (Standard) 133868-46-9 98%
    Valnemulin (hydrochloride) (Standard) is the analytical standard of Valnemulin (hydrochloride). This product is intended for research and analytical applications. Valnemulin (hydrochloride) is an orally effective truncated pleurotin antibiotic that inhibits protein synthesis in bacteria by binding to peptidyl transferase in the 50s ribosome subunit. Valnemulin hydrochloride effectively eliminates Mycobacterium bovis in the lungs in an experimental bovine model of Mycoplasma bovis infection. Valnemulin hydrochloride can reduce the mortality of epidemic rabbit enteropathy and has no adverse effect on the growth performance of rabbits.
    Valnemulin hydrochloride (Standard)
  • HY-B0144S
    Pitavastatin-d4 hemicalcium 98%
    Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
    Pitavastatin-d4 hemicalcium
  • HY-B0160S
    Lafutidine-d10 1795136-26-3 98%
    Lafutidine-d10 is deuterium labeled Lafutidine. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease.
    Lafutidine-d10
  • HY-B0224A
    Chlorothiazide sodium 7085-44-1 98%
    Chlorothiazide sodium is an orally active diuretic and anti-hypertensive agent.
    Chlorothiazide sodium
  • HY-B0227R
    Ketoprofen (Standard) 22071-15-4 98%
    Ketoprofen (Standard) is the analytical standard of Ketoprofen. This product is intended for research and analytical applications. Ketoprofen (RP-19583) is a non-steroidal anti-inflammatory agent. Ketoprofen can inhibits the activity of cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.
    Ketoprofen (Standard)
  • HY-B0235A
    Trichlormethiazide sodium 91996-54-2 98%
    Trichlormethiazide sodium is an orally active thiazide diuretic, with antihypertensive effect. Trichlormethiazide sodium increases urine volume (UV), Na and K excretion and tends to improve the depressed creatinine clearance (CCRE) in acute renal failure rats model.
    Trichlormethiazide sodium
  • HY-B0236A
    6-Aminocaproic acid hydrochloride 4321-58-8 98%
    6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
    6-Aminocaproic acid hydrochloride
  • HY-B0236R
    6-Aminocaproic acid (Standard) 60-32-2 98%
    6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders.
    6-Aminocaproic acid (Standard)
  • HY-B0262S
    Methocarbamol-d5 1189699-70-4 98%
    Methocarbamol-d5 is deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel.
    Methocarbamol-d5
  • HY-B0283S
    Acipimox-d4 1246816-28-3 98%
    Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
    Acipimox-d4
  • HY-B0287S
    Clofibrate-d4 1189654-03-2 98%
    Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
    Clofibrate-d4
Cat. No. Product Name / Synonyms Application Reactivity